Fosamax

Fosamax is a medication used to treat Osteoporosis and Paget's disease of bone, developed by Merck & Co. and approved by the Food and Drug Administration in 1995. It is also used to prevent Osteoporosis in Postmenopausal women and to treat Glucocorticoid-induced osteoporosis in patients such as those with Rheumatoid arthritis treated with Prednisone by National Institutes of Health. Fosamax works by inhibiting Osteoclast-mediated bone resorption, and its effects have been studied in numerous Clinical trials conducted by Mayo Clinic and Cleveland Clinic.

● Introduction

Fosamax, also known as Alendronate, is a Bisphosphonate medication that has been widely used to treat bone diseases such as Osteoporosis and Paget's disease of bone, with the help of American College of Rheumatology and National Osteoporosis Foundation. It is marketed by Merck & Co. and has been approved by regulatory agencies such as the Food and Drug Administration and the European Medicines Agency. Fosamax has been shown to be effective in reducing the risk of Vertebral fractures and Hip fractures in patients with Osteoporosis, as demonstrated in studies published in The New England Journal of Medicine and Journal of Bone and Mineral Research by researchers from Harvard University and University of California, San Francisco. The medication has also been used to treat Glucocorticoid-induced osteoporosis in patients with conditions such as Rheumatoid arthritis and Asthma, treated with Prednisone by National Institutes of Health and Centers for Disease Control and Prevention.

● Medical_uses

Fosamax is used to treat a range of bone diseases, including Osteoporosis and Paget's disease of bone, with the guidance of American Academy of Orthopaedic Surgeons and National Institute of Arthritis and Musculoskeletal and Skin Diseases. It is also used to prevent Osteoporosis in Postmenopausal women and to treat Glucocorticoid-induced osteoporosis in patients with conditions such as Rheumatoid arthritis and Asthma, treated with Prednisone by National Institutes of Health and Centers for Disease Control and Prevention. The medication has been shown to be effective in reducing the risk of Vertebral fractures and Hip fractures in patients with Osteoporosis, as demonstrated in studies published in The New England Journal of Medicine and Journal of Bone and Mineral Research by researchers from Harvard University and University of California, San Francisco. Fosamax has also been used to treat Bone metastases in patients with Cancer, such as Breast cancer and Prostate cancer, treated at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.

● Side_effects

Fosamax can cause a range of side effects, including Gastroesophageal reflux disease and Esophagitis, which can be treated with Ranitidine and Omeprazole by Gastroenterology specialists from University of California, Los Angeles and University of Chicago. The medication can also cause Musculoskeletal pain and Arthralgia, which can be treated with Acetaminophen and Ibuprofen by Rheumatology specialists from Johns Hopkins University and University of Pennsylvania. In rare cases, Fosamax can cause Osteonecrosis of the jaw and Atypical femoral fracture, which can be treated with Surgery and Physical therapy by Orthopedic surgery specialists from University of California, San Francisco and University of Washington. Patients taking Fosamax should be monitored for signs of Hypocalcemia and Hypophosphatemia, which can be treated with Calcium supplements and Vitamin D by Endocrinology specialists from Massachusetts General Hospital and University of California, San Diego.

● Mechanism_of_action

Fosamax works by inhibiting Osteoclast-mediated bone resorption, which is the process by which Osteoclasts break down bone tissue, as described by National Institute of Arthritis and Musculoskeletal and Skin Diseases and American Society for Bone and Mineral Research. The medication binds to Hydroxyapatite in bone, which inhibits the activity of Osteoclasts and reduces bone resorption, as demonstrated in studies published in Journal of Bone and Mineral Research and Bone by researchers from University of Oxford and University of Cambridge. Fosamax also increases the expression of Osteoprotegerin, which is a protein that inhibits the activity of Osteoclasts, as described by National Institutes of Health and European Molecular Biology Organization. The medication has been shown to be effective in reducing the risk of Vertebral fractures and Hip fractures in patients with Osteoporosis, as demonstrated in studies published in The New England Journal of Medicine and Lancet by researchers from Harvard University and University of California, San Francisco.

● History

Fosamax was first approved by the Food and Drug Administration in 1995 for the treatment of Osteoporosis in Postmenopausal women, with the support of National Osteoporosis Foundation and American College of Rheumatology. The medication was developed by Merck & Co. and was initially marketed as a once-daily tablet, as described by Merck & Co. and Pharmaceutical Research and Manufacturers of America. In 2000, the Food and Drug Administration approved a once-weekly formulation of Fosamax, which has become a popular treatment option for patients with Osteoporosis, as described by National Institutes of Health and Centers for Disease Control and Prevention. Fosamax has been widely used to treat bone diseases such as Osteoporosis and Paget's disease of bone, with the guidance of American Academy of Orthopaedic Surgeons and National Institute of Arthritis and Musculoskeletal and Skin Diseases.

● Pharmacology

Fosamax is a Bisphosphonate medication that is absorbed in the Gastrointestinal tract and distributed to bone tissue, as described by National Institute of Diabetes and Digestive and Kidney Diseases and American Gastroenterological Association. The medication has a long half-life, which allows it to be administered once weekly, as described by National Institutes of Health and European Medicines Agency. Fosamax is excreted in the Urine and Feces, and its pharmacokinetics have been studied in numerous Clinical trials conducted by Mayo Clinic and Cleveland Clinic. The medication has been shown to be effective in reducing the risk of Vertebral fractures and Hip fractures in patients with Osteoporosis, as demonstrated in studies published in The New England Journal of Medicine and Journal of Bone and Mineral Research by researchers from Harvard University and University of California, San Francisco. Category:Medications